GlassScriptPhysician profile
Kinsey Mccartney
NPI 1972880102
$13,163.20
in general payments reported to CMS, 2019-2025
27 companies · $6,506 in 2025
The $6,506 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,148 · 2022: $2,408 · 2023: $1,838 · 2024: $264 · 2025: $6,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,400 · Food and Beverage: $3,221 · Travel and Lodging: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,400.00 |
| Food and Beverage | $3,220.51 |
| Travel and Lodging | $987.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,611.02 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,047.00 | 2021-2025 | Nuplazid |
| Merz Pharmaceuticals, LLC | $888.18 | 2021-2023 | Xeomin |
| Kyowa Kirin, INC. | $471.68 | 2021-2023 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $388.26 | 2021-2023 | Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $364.22 | 2021-2023 | Ongentys, Ingrezza |
| Sunovion Pharmaceuticals INC. | $318.54 | 2021-2022 | |
| Abbott Laboratories | $313.77 | 2021-2025 | Infinity |
| Amneal Pharmaceuticals LLC | $255.71 | 2021-2023 | Rytary |
| Medtronic, INC. | $214.31 | 2021-2022 | |
| Boston Scientific Corporation | $190.91 | 2022-2025 | General - Dbs |
| Acorda Therapeutics, INC | $168.88 | 2021-2023 | Inbrija |
| Allergan, INC. | $137.34 | 2021-2022 | |
| Mdd US Operations, LLC | $134.36 | 2022-2023 | Gocovri |
| Avion Pharmaceuticals | $108.68 | 2022-2023 | Dhivy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $93.40 | 2021-2022 | |
| Ge Healthcare | $87.94 | 2022-2023 | |
| Adamas Pharmaceuticals, INC. | $82.22 | 2021 | |
| Avanir Pharmaceuticals, INC. | $54.80 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $48.05 | 2022-2023 | Horizant |
| Insightec,INC | $38.47 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $36.75 | 2022 | |
| Ucb, INC. | $30.75 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.26 | 2023 | Nuedexta |
| Cala Health, INC. | $19.05 | 2022 | |
| Corium, LLC | $18.63 | 2022 | |
| Eisai INC. | $17.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinsey Mccartney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.